U.S. Department of Health & Human Services Divider Arrow National Institutes of Health Divider Arrow NCATS

Details

Stereochemistry ACHIRAL
Molecular Formula CH5N3
Molecular Weight 59.0705
Optical Activity NONE
Defined Stereocenters 0 / 0
E/Z Centers 0
Charge 0

SHOW SMILES / InChI
Structure of GUANIDINE

SMILES

C(=N)(N)N

InChI

InChIKey=ZRALSGWEFCBTJO-UHFFFAOYSA-N
InChI=1S/CH5N3/c2-1(3)4/h(H5,2,3,4)

HIDE SMILES / InChI

Molecular Formula CH5N3
Molecular Weight 59.0705
Charge 0
Count
Stereochemistry ACHIRAL
Additional Stereochemistry No
Defined Stereocenters 0 / 0
E/Z Centers 0
Optical Activity NONE

Guanidine is a small basic compound. Guanidine stimulates the neuromuscular junction presynaptically by inhibiting voltage-gated potassium (Kv) channels, leading to the enhanced release of acetylcholine in the synaptic cleft. This stimulatory effect of guanidine underlies its use in the therapy for the neuromuscular diseases. The hydrochloride salt of guanidine was approved by FDA for the reduction of the symptoms of muscle weakness and easy fatigability associated with the myasthenic syndrome of Eaton-Lambert.

CNS Activity

Curator's Comment:: The study was performed on rats.

Originator

Curator's Comment:: Original article: A. Strecker, Liebigs Ann. Chem. 1861, 118, 151-177.

Approval Year

Targets

Targets

Primary TargetPharmacologyConditionPotency
Conditions

Conditions

ConditionModalityTargetsHighest PhaseProduct
Palliative
GUANIDINE HYDROCHLORIDE

Approved Use

Guanidine is indicated for the reduction of the symptoms of muscle weakness and easy fatigability associated with the myasthenic syndrome of Eaton-Lambert. It is not indicated for treating myasthenia gravis. The Eaton-Lambert syndrome is ordinarily differentiated from myasthenia gravis by the usual association of the syndrome with small cell carcinoma of the lung, but myography may be necessary to make the diagnosis.

Launch Date

-9.5463362E11
PubMed

PubMed

TitleDatePubMed
Selective substrates for non-neuronal monoamine transporters.
1999 Jul
The relationship of the factor V Leiden mutation or the deletion-deletion polymorphism of the angiotensin converting enzyme to postoperative thromboembolic events following total joint arthroplasty.
2001
Isolation and characterization of a xylose-glucose isomerase from a new strain Streptomyces thermovulgaris 127, var. 7-86.
2001
Topological diversity of artificial beta-barrels in water.
2001
Structure-activity relationship (SAR) studies on oxazolidinone antibacterial agents. 1. Conversion of 5-substituent on oxazolidinone.
2001 Apr
High-sensitivity fluorescence anisotropy detection of protein-folding events: application to alpha-lactalbumin.
2001 Apr
Synthesis and biological activity of analogues of the antidiabetic/antiobesity agent 3-guanidinopropionic acid: discovery of a novel aminoguanidinoacetic acid antidiabetic agent.
2001 Apr 12
Second-site revertants of a low-sodium-affinity mutant of the Na+/H+ exchanger reveal the participation of TM4 into a highly constrained sodium-binding site.
2001 Apr 24
Equilibrium unfolding of dimeric desulfoferrodoxin involves a monomeric intermediate: iron cofactors dissociate after polypeptide unfolding.
2001 Apr 24
Probing copper ligands in denatured Pseudomonas aeruginosa azurin: unfolding His117Gly and His46Gly mutants.
2001 Feb
Species-specific PCR for the identification of ovine, porcine and chicken species in meta and bone meal (MBM).
2001 Feb
Uremic concentrations of guanidino compounds inhibit neutrophil superoxide production.
2001 Feb
Apparent two-state tendamistat folding is a sequential process along a defined route.
2001 Feb 16
Rate of intrachain contact formation in an unfolded protein: temperature and denaturant effects.
2001 Feb 2
Efficient gene transfection by bisguanylated diacetylene lipid formulations.
2001 Feb 23
Phaeochromocytoma: an unusual cause of hypertension in pregnancy.
2001 Jan
Detection of enterovirus and hepatitis A virus RNA in mussels (Mytilus spp.) by reverse transcriptase-polymerase chain reaction.
2001 Jan
Cellular responses of NG108-15 and SK-N-MC lines to sweet and bitter tastants as measured by extracellular acidification rates.
2001 Jan 1
Folding-unfolding of goat alpha-lactalbumin studied by stopped-flow circular dichroism and molecular dynamics simulations.
2001 Jan 1
Conformational origin of the aggregation of recombinant human factor VIII.
2001 Jan 16
Achieving stability and conformational specificity in designed proteins via binary patterning.
2001 Jan 19
A kinetic folding intermediate probed by native state hydrogen exchange.
2001 Jan 19
Engineering conformational flexibility in the lactose permease of Escherichia coli: use of glycine-scanning mutagenesis to rescue mutant Glu325-->Asp.
2001 Jan 23
A rigid linker-scaffold for solid-phase synthesis of dimeric pharmacophores.
2001 Jan-Feb
Protein compactness measured by fluorescence resonance energy transfer. Human carbonic anhydrase ii is considerably expanded by the interaction of GroEL.
2001 Jun 15
Elucidation of a [4Fe-4S] cluster degradation pathway: rapid kinetic studies of the degradation of Chromatium vinosum HiPIP.
2001 Mar
Cutinase unfolding and stabilization by trehalose and mannosylglycerate.
2001 Mar 1
Major differences in stability and dimerization properties of two chimeric mutants of human stefins.
2001 Mar 1
The synthesis of beta-peptides containing guanidino groups.
2001 Mar 12
An N-terminal three-helix fragment of the exchangeable insect apolipoprotein apolipophorin III conserves the lipid binding properties of wild-type protein.
2001 Mar 13
Mutagenesis of two acidic active site residues in human muscle creatine kinase: implications for the catalytic mechanism.
2001 Mar 13
Dramatic stabilization of an SH3 domain by a single substitution: roles of the folded and unfolded states.
2001 Mar 30
The dimerization of folded monomers of ribulose 1,5-bisphosphate carboxylase/oxygenase.
2001 Mar 9
Proton and metal ion-dependent assembly of a model diiron protein.
2001 May
Cyclic green fluorescent protein produced in vivo using an artificially split PI-PfuI intein from Pyrococcus furiosus.
2001 May 11
Guanidino-containing drugs in cancer chemotherapy: biochemical and clinical pharmacology.
2001 May 15
Folding intermediates of a model three-helix bundle protein. Pressure and cold denaturation studies.
2001 May 4
Patents

Sample Use Guides

Initial dosage is usually between 10 and 15 mg/kg (5 to 7 mg/pound) of body weight per day in 3 or 4 divided doses. This dosage may be gradually increased to a total daily dosage of 35 mg/kg (16 mg/pound) of body weight per day or up to the development of side effects.
Route of Administration: Oral
In Vitro Use Guide
Mice spinal cord neurons were treated with guanidine at concentrations between 100 nM and 100 mM. At 100 mM induced a membrane depolarization of 10 to 25 mV and rapidly and reversibly reduced GABA responses: 23.9% decrease of GABA responses was obtained with 10 mM guanidine and complete inhibition was observed with 100 mM). It also significantly reduced Glycine response at 10 mM.
Substance Class Chemical
Created
by admin
on Fri Jun 25 22:35:41 UTC 2021
Edited
by admin
on Fri Jun 25 22:35:41 UTC 2021
Record UNII
JU58VJ6Y3B
Record Status Validated (UNII)
Record Version
  • Download
Name Type Language
GUANIDINE
HSDB   MI   VANDF   WHO-DD  
Systematic Name English
GUANIDINE [MI]
Common Name English
IMIDOUREA
Common Name English
GUANIDINE [WHO-DD]
Common Name English
GUANIDINE [HSDB]
Common Name English
GUANIDINE [VANDF]
Common Name English
Classification Tree Code System Code
NCI_THESAURUS C45564
Created by admin on Fri Jun 25 22:35:41 UTC 2021 , Edited by admin on Fri Jun 25 22:35:41 UTC 2021
NDF-RT N0000175772
Created by admin on Fri Jun 25 22:35:41 UTC 2021 , Edited by admin on Fri Jun 25 22:35:41 UTC 2021
NDF-RT N0000009079
Created by admin on Fri Jun 25 22:35:41 UTC 2021 , Edited by admin on Fri Jun 25 22:35:41 UTC 2021
Code System Code Type Description
EPA CompTox
113-00-8
Created by admin on Fri Jun 25 22:35:41 UTC 2021 , Edited by admin on Fri Jun 25 22:35:41 UTC 2021
PRIMARY
DRUG BANK
DB00536
Created by admin on Fri Jun 25 22:35:41 UTC 2021 , Edited by admin on Fri Jun 25 22:35:41 UTC 2021
PRIMARY
CAS
113-00-8
Created by admin on Fri Jun 25 22:35:41 UTC 2021 , Edited by admin on Fri Jun 25 22:35:41 UTC 2021
PRIMARY
RXCUI
50675
Created by admin on Fri Jun 25 22:35:41 UTC 2021 , Edited by admin on Fri Jun 25 22:35:41 UTC 2021
PRIMARY RxNorm
MESH
D019791
Created by admin on Fri Jun 25 22:35:41 UTC 2021 , Edited by admin on Fri Jun 25 22:35:41 UTC 2021
PRIMARY
EVMPD
SUB14034MIG
Created by admin on Fri Jun 25 22:35:41 UTC 2021 , Edited by admin on Fri Jun 25 22:35:41 UTC 2021
PRIMARY
NCI_THESAURUS
C77851
Created by admin on Fri Jun 25 22:35:41 UTC 2021 , Edited by admin on Fri Jun 25 22:35:41 UTC 2021
PRIMARY
HSDB
7603
Created by admin on Fri Jun 25 22:35:41 UTC 2021 , Edited by admin on Fri Jun 25 22:35:41 UTC 2021
PRIMARY
MERCK INDEX
M5867
Created by admin on Fri Jun 25 22:35:41 UTC 2021 , Edited by admin on Fri Jun 25 22:35:41 UTC 2021
PRIMARY Merck Index
ECHA (EC/EINECS)
204-021-8
Created by admin on Fri Jun 25 22:35:41 UTC 2021 , Edited by admin on Fri Jun 25 22:35:41 UTC 2021
PRIMARY
FDA UNII
JU58VJ6Y3B
Created by admin on Fri Jun 25 22:35:41 UTC 2021 , Edited by admin on Fri Jun 25 22:35:41 UTC 2021
PRIMARY
WIKIPEDIA
GUANIDINE
Created by admin on Fri Jun 25 22:35:41 UTC 2021 , Edited by admin on Fri Jun 25 22:35:41 UTC 2021
PRIMARY
IUPHAR
4783
Created by admin on Fri Jun 25 22:35:41 UTC 2021 , Edited by admin on Fri Jun 25 22:35:41 UTC 2021
PRIMARY
DRUG CENTRAL
1344
Created by admin on Fri Jun 25 22:35:41 UTC 2021 , Edited by admin on Fri Jun 25 22:35:41 UTC 2021
PRIMARY
PUBCHEM
3520
Created by admin on Fri Jun 25 22:35:41 UTC 2021 , Edited by admin on Fri Jun 25 22:35:41 UTC 2021
PRIMARY
Related Record Type Details
SALT/SOLVATE -> PARENT
TRANSPORTER -> SUBSTRATE
Vmax
TRANSPORTER -> SUBSTRATE
Km
TRANSPORTER -> SUBSTRATE
Km
SALT/SOLVATE -> PARENT
TRANSPORTER -> INHIBITOR
TRANSPORTER -> SUBSTRATE
Vmax
Related Record Type Details
ACTIVE MOIETY